Dicuno: Uses, Dosage & Side Effects

What Is Dicuno and What Is It Used For?

Dicuno contains diclofenac potassium as its active ingredient, belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Diclofenac is one of the most widely prescribed NSAIDs globally and is included in the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in clinical practice. The drug was first synthesized in the 1960s and has accumulated over five decades of clinical experience, making it one of the most extensively studied analgesic and anti-inflammatory agents available.

Diclofenac exerts its therapeutic effects primarily through the inhibition of cyclooxygenase enzymes, specifically both COX-1 and COX-2. These enzymes catalyse the conversion of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes—lipid mediators that play central roles in inflammation, pain perception, and thermoregulation. By blocking the production of prostaglandins at sites of tissue injury and inflammation, diclofenac reduces the cardinal signs of inflammation: redness (rubor), swelling (tumour), heat (calor), pain (dolor), and loss of function (functio laesa). Additionally, diclofenac has been shown to have effects beyond COX inhibition, including modulation of the arachidonic acid–leukotriene pathway, inhibition of thromboxane–prostanoid receptor signaling, and activation of the nitric oxide–cGMP antinociceptive pathway.

The potassium salt formulation of diclofenac in Dicuno offers a distinct pharmacokinetic advantage over the more common sodium salt. Diclofenac potassium dissolves more rapidly in the acidic environment of the stomach, leading to faster absorption and earlier attainment of peak plasma concentrations. While diclofenac sodium typically reaches peak plasma levels in 1–2 hours, diclofenac potassium achieves peak concentrations within 20–60 minutes after oral administration. This faster onset makes Dicuno particularly well-suited for conditions where rapid pain relief is desired, such as acute migraine attacks, dental pain following procedures, and primary dysmenorrhoea.

Despite its relatively short plasma half-life of approximately 1–2 hours, diclofenac demonstrates a duration of analgesic and anti-inflammatory action that substantially exceeds what would be predicted from its plasma pharmacokinetics alone. This phenomenon is explained by diclofenac’s ability to accumulate in inflamed tissues and synovial fluid, where concentrations can persist at therapeutic levels well after plasma levels have declined. In patients with joint inflammation, for example, synovial fluid concentrations of diclofenac remain elevated for 4–8 hours after a single oral dose, providing sustained relief at the site of pathology.

Dicuno is indicated for a broad range of conditions where pain, inflammation, or fever are prominent features:

• Osteoarthritis: The most common form of arthritis, characterised by progressive degradation of joint cartilage. Diclofenac provides symptomatic relief of joint pain, stiffness, and swelling, and is recommended in international guidelines (ACR, EULAR, NICE) as an option for patients who do not obtain adequate relief from paracetamol alone.
• Rheumatoid arthritis: A chronic autoimmune inflammatory joint disease. Diclofenac helps manage pain and morning stiffness while disease-modifying antirheumatic drugs (DMARDs) work to control the underlying disease process.
• Acute musculoskeletal pain: Including sprains, strains, sports injuries, and back pain. Diclofenac provides effective short-term relief and is often used as first-line pharmacotherapy in combination with physical therapy.
• Primary dysmenorrhoea: Menstrual pain caused by excess prostaglandin production in the uterus. NSAIDs such as diclofenac are considered first-line treatment, and the rapid onset of the potassium salt formulation is particularly advantageous for this indication.
• Migraine attacks: Diclofenac potassium has demonstrated efficacy in the acute treatment of migraine headache, with studies showing significant pain relief at 2 hours compared to placebo. Its fast absorption profile makes it a suitable option for patients who need rapid relief.
• Dental pain: Post-extraction and post-procedural dental pain responds well to diclofenac. The 25 mg dose can be titrated as needed, and the analgesic effect is typically apparent within 30 minutes.
• Post-operative pain: Following minor surgical procedures, diclofenac can be used alone or in combination with paracetamol for effective multimodal analgesia, potentially reducing the need for opioid analgesics.
• Acute gout: The intense inflammatory pain of acute gouty arthritis is highly responsive to NSAIDs. Diclofenac is one of the recommended first-line options for acute gout flares.

What Should You Know Before Taking Dicuno?

Contraindications

Dicuno must not be used in the following circumstances, as serious or life-threatening harm may result:

• Hypersensitivity: Known allergy to diclofenac, to any of the excipients in the tablet, or to other NSAIDs. This includes patients who have experienced asthma, urticaria (hives), angioedema, or rhinitis after taking aspirin or any other NSAID (sometimes called the “aspirin triad” or NSAID-exacerbated respiratory disease).
• Active gastrointestinal bleeding or ulceration: Patients with current peptic ulcer disease, GI bleeding, or a history of GI perforation related to previous NSAID therapy.
• Severe heart failure: NYHA class III–IV heart failure, as NSAIDs can cause fluid retention and oedema that may worsen cardiac function.
• Severe hepatic impairment: Patients with severe liver disease (Child-Pugh class C) should not use diclofenac due to the risk of further hepatic injury.
• Severe renal impairment: Patients with a creatinine clearance below 30 mL/min, as diclofenac can further impair renal function through inhibition of prostaglandin-mediated renal blood flow.
• Third trimester of pregnancy: All NSAIDs are contraindicated from gestational week 20 onwards due to the risk of premature closure of the ductus arteriosus, oligohydramnios from fetal renal dysfunction, and inhibition of labour.
• Peri-operative period in coronary artery bypass graft (CABG) surgery: NSAIDs are contraindicated in this setting due to significantly increased cardiovascular risk.

Warnings and Precautions

Before starting Dicuno, discuss the following conditions and risk factors with your healthcare provider:

• Cardiovascular disease: Diclofenac has been associated with an increased risk of arterial thrombotic events, including myocardial infarction and stroke. A meta-analysis published in The Lancet (Coxib and traditional NSAID Trialists’ Collaboration, 2013) found that diclofenac 150 mg daily was associated with a relative risk of major vascular events comparable to selective COX-2 inhibitors. Patients with established cardiovascular disease, uncontrolled hypertension, hyperlipidaemia, diabetes mellitus, or those who smoke should use diclofenac with particular caution and only after careful risk-benefit assessment.
• Gastrointestinal risk: NSAIDs can cause peptic ulcers, GI bleeding, and perforation at any time during treatment, often without warning symptoms. Risk factors include older age, prior GI history, concomitant use of oral corticosteroids, anticoagulants, SSRIs, or other NSAIDs, and heavy alcohol consumption. Consider co-prescription of a proton pump inhibitor (PPI) for patients at increased GI risk.
• Renal function: Prostaglandins play an important role in maintaining renal blood flow, particularly in patients with reduced effective blood volume (heart failure, cirrhosis, dehydration) or pre-existing renal impairment. NSAIDs can precipitate acute kidney injury in these situations. Monitor renal function before and during treatment in at-risk patients.
• Hepatic function: Elevations of liver transaminases (ALT, AST) have been reported with diclofenac use. In rare cases, severe hepatic reactions including fulminant hepatitis, liver necrosis, and hepatic failure have occurred. Monitor liver function during long-term therapy and discontinue immediately if abnormal liver function tests persist or worsen.
• Fluid retention and oedema: NSAIDs can cause fluid retention and peripheral oedema. Use with caution in patients with hypertension or heart failure.
• Elderly patients: Older adults are at increased risk of serious NSAID-related adverse effects, particularly GI bleeding and renal impairment. Use the lowest effective dose for the shortest possible duration and consider gastroprotection.

Pregnancy and Breastfeeding

Dicuno is contraindicated during the third trimester of pregnancy and should generally be avoided from gestational week 20 onwards. Use of NSAIDs during this period can cause premature closure of the fetal ductus arteriosus, oligohydramnios due to impaired fetal renal function, and delayed or prolonged labour. During the first and second trimesters, diclofenac should only be used if the potential benefit justifies the potential risk to the fetus. Animal studies have shown reproductive toxicity at high doses, including delayed ossification and increased peri-natal mortality.

Diclofenac passes into breast milk in small amounts. Based on the low levels measured in breast milk and the short half-life of the drug, the risk to the nursing infant is considered low. However, as a precaution, Dicuno should be avoided during breastfeeding unless clearly necessary. If use is deemed essential, the infant should be monitored for any adverse effects. Consult your doctor before taking any NSAID while breastfeeding.

Driving and Operating Machinery

Diclofenac can occasionally cause dizziness, drowsiness, visual disturbances, or fatigue. Patients who experience these side effects should not drive or operate heavy machinery. If you are affected, avoid these activities until the symptoms have resolved. These effects are generally more likely at the start of treatment or when the dose is increased.

How Does Dicuno Interact with Other Drugs?

Diclofenac, like other NSAIDs, has a well-characterised drug interaction profile that clinicians and patients should be aware of. Unlike monoclonal antibodies that have few drug interactions, small-molecule NSAIDs are metabolised by hepatic cytochrome P450 enzymes (primarily CYP2C9) and are highly protein-bound (>99%), creating multiple opportunities for pharmacokinetic and pharmacodynamic interactions with other medications. Understanding these interactions is essential for safe prescribing and use of Dicuno.

Major Interactions

The following interactions are considered clinically significant and may require dose adjustment, alternative therapy, or close monitoring:

Minor Interactions and Considerations

In addition to the major interactions listed above, the following interactions are worth noting, although they are generally of lesser clinical significance:

• Digoxin: Diclofenac may increase plasma digoxin levels by reducing renal clearance. Monitor digoxin levels if initiating or discontinuing diclofenac in patients on digoxin therapy.
• Phenytoin: Diclofenac may increase free phenytoin levels through displacement from plasma protein binding sites. Monitor phenytoin levels and adjust doses as necessary.
• Oral hypoglycaemics: Isolated reports suggest that diclofenac may affect blood glucose levels. While the clinical significance is generally low, patients with diabetes should monitor their blood glucose more closely when starting or stopping diclofenac.
• Quinolone antibiotics: Concomitant use of NSAIDs and quinolones (e.g., ciprofloxacin) may increase the risk of seizures. Use the combination with caution, particularly in patients with a history of epilepsy.
• Corticosteroids: Concurrent use increases the risk of GI ulceration and bleeding. Consider gastroprotection with a PPI.
• Paracetamol (acetaminophen): Can be used together as they work through different mechanisms. The combination may provide superior analgesia compared to either agent alone and can help reduce the required NSAID dose.

What Is the Correct Dosage of Dicuno?

Dicuno should always be used exactly as prescribed by your doctor. The fundamental principle governing NSAID dosing—including Dicuno—is to use the lowest effective dose for the shortest duration necessary to control symptoms. This approach minimises the risk of cardiovascular, gastrointestinal, and renal adverse effects while providing adequate therapeutic benefit. Tablets should be swallowed whole with water, preferably with or after food to reduce the risk of gastrointestinal irritation.

Adults

The 25 mg tablet strength in Dicuno provides dosing flexibility, allowing patients and clinicians to start at lower doses and titrate upward as needed. For many mild to moderate pain conditions, an initial dose of 25 mg three times daily (75 mg/day) may be sufficient. The dose can be increased to a maximum of 150 mg daily if clinically necessary. For acute conditions requiring rapid relief, an initial higher dose (e.g., 50 mg or 75 mg as two to three 25 mg tablets) may be used, followed by lower maintenance doses.

Children and Adolescents

Dicuno 25 mg film-coated tablets are generally not recommended for children under 14 years of age. For adolescents aged 14 years and over weighing at least 50 kg, a dose of 25–50 mg two to three times daily may be used, with a maximum daily dose of 150 mg or 2 mg/kg body weight (whichever is lower). In children aged 1–13 years, other diclofenac formulations (such as suppositories or oral suspension) may be more appropriate, and the dose should be based on body weight (typically 1–3 mg/kg/day in divided doses). Always consult a paediatrician before using any NSAID in children.

Elderly Patients

Elderly patients are at increased risk of serious adverse effects from NSAIDs, including GI bleeding, cardiovascular events, and renal impairment. The lowest effective dose should be used, and treatment duration should be kept as short as possible. A starting dose of 25 mg two to three times daily is generally recommended in elderly patients, with careful upward titration only if needed. Co-prescription of a proton pump inhibitor (PPI) should be considered for gastroprotection. Regular monitoring of renal function, hepatic function, and blood pressure is advisable during treatment.

Missed Dose

If you miss a dose of Dicuno, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you are using Dicuno on an “as needed” basis for acute pain, simply take the next dose when pain returns.

Overdose

Symptoms of diclofenac overdose may include nausea, vomiting, abdominal pain, gastrointestinal bleeding, diarrhoea, dizziness, tinnitus, drowsiness, and in severe cases, acute renal failure, liver damage, or rarely, seizures and cardiovascular collapse. There is no specific antidote for diclofenac overdose. Treatment is supportive and symptomatic, including gastric decontamination (activated charcoal if within 1 hour of ingestion), monitoring of vital signs, renal function, and liver function, and management of GI bleeding if present. In the event of a suspected overdose, seek immediate medical attention or contact your local poison control centre.

What Are the Side Effects of Dicuno?

Like all medicines, Dicuno can cause side effects, although not everybody experiences them. The side effects of diclofenac are well-characterised from decades of clinical use and post-marketing surveillance involving millions of patients worldwide. Most side effects are mild and transient, but some can be serious. The following frequency categories are based on internationally standardised reporting conventions used by the European Medicines Agency and the FDA:

The gastrointestinal side effects of diclofenac are among the most clinically important. Prostaglandins produced by COX-1 play a protective role in the gastric mucosa by promoting bicarbonate and mucus secretion, maintaining mucosal blood flow, and supporting epithelial cell turnover. By inhibiting COX-1, diclofenac reduces these protective factors, increasing susceptibility to acid-mediated mucosal damage. The risk of serious GI events is estimated at approximately 1–4% per year of NSAID use, with the risk being highest in the first few months of treatment.

Cardiovascular risks associated with diclofenac have received considerable attention following the publication of large-scale meta-analyses. The CNT Collaboration meta-analysis (2013) found that diclofenac 150 mg/day was associated with approximately 3 additional major vascular events per 1,000 patient-years in low-risk individuals, with higher absolute risks in patients with pre-existing cardiovascular disease. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has issued recommendations that diclofenac should be used with the same precautions as selective COX-2 inhibitors regarding cardiovascular risk.

Hepatotoxicity is an important class effect of diclofenac. Elevated liver enzymes (ALT or AST exceeding three times the upper limit of normal) occur in approximately 2–4% of patients receiving long-term diclofenac therapy. In most cases, these elevations are asymptomatic and reversible upon discontinuation. However, rare cases of severe hepatic injury, including fulminant hepatitis, have been reported. Regular monitoring of liver function is recommended for patients receiving diclofenac for longer than 4 weeks.

How Should You Store Dicuno?

Proper storage of medications is essential to maintain their efficacy and safety throughout the shelf life. Dicuno 25 mg film-coated tablets should be stored in accordance with the following guidelines:

• Temperature: Store at or below 25°C (77°F). Do not freeze. Brief exposure to temperatures up to 30°C during transport is generally acceptable, but prolonged exposure to high temperatures may affect tablet stability.
• Packaging: Keep the tablets in their original blister packaging or container until use. This protects them from moisture and light, which can degrade the active ingredient.
• Moisture: Protect from humidity. Do not store in the bathroom or near a sink, as these areas are prone to high humidity. If the original packaging is a bottle, ensure the cap is tightly closed after each use.
• Light: Protect from direct sunlight and strong artificial light. Diclofenac can undergo photodegradation if exposed to intense light for extended periods.
• Children: Keep out of the sight and reach of children. Store in a locked medicine cabinet if possible. NSAID ingestion in children can cause serious toxicity.
• Expiry date: Do not use Dicuno after the expiry date (EXP) printed on the blister or carton. The expiry date refers to the last day of that month. Expired medications should not be used and should be returned to a pharmacy for proper disposal.

Do not dispose of unused or expired medicines via household waste or by flushing them down the toilet. Return them to your local pharmacy, which will ensure they are disposed of in an environmentally responsible manner in accordance with local regulations. Many countries operate take-back programmes specifically for this purpose.

What Does Dicuno Contain?

Each Dicuno 25 mg film-coated tablet contains the following:

• Active ingredient: Diclofenac potassium 25 mg. This is the pharmacologically active component responsible for the drug’s analgesic, anti-inflammatory, and antipyretic effects. The potassium salt is chosen for its superior dissolution properties compared to the sodium salt.
• Core excipients (inactive ingredients): The tablet core typically contains microcrystalline cellulose (a binder and filler), lactose monohydrate (a filler—patients with lactose intolerance should be aware), maize starch (a disintegrant that helps the tablet break apart in the stomach), colloidal anhydrous silica (a flow agent), magnesium stearate (a lubricant), and povidone (a binder).
• Film coating: The coating is composed of hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171, a white colouring agent), macrogol/polyethylene glycol (a plasticiser), talc (a coating agent), and may contain iron oxide pigments for colour (depending on the specific market formulation).

Patients with known allergies or intolerances to any of these ingredients should inform their healthcare provider before using Dicuno. Of particular note, the tablets contain lactose monohydrate, which may be relevant for patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. The amount of lactose per tablet is small but should be considered in patients with these conditions.

The film coating serves several purposes: it makes the tablet easier to swallow, protects the active ingredient from light and moisture degradation, and can help mask the taste of the active substance. The coating does not significantly affect the dissolution or absorption profile of the diclofenac potassium contained within.